NCT01755572 - Blood Pressure Outcomes With Liraglutide Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

March 31, 2014

Conditions

Type 2 DiabetesSystolic Hypertension

Interventions

DRUG

Liraglutide

Single cross-over study, 1 arm starting with liraglutide for 3 weeks crossed-over to placebo for 3 weeks, and 1 arm starting with placebo with cross-over to liraglutide for 3 weeks.

DRUG

Placebo

Single cross-over study, 1 arm starting with liraglutide for 3 weeks crossed-over to placebo for 3 weeks, and 1 arm starting with placebo with cross-over to liraglutide for 3 weeks.

Trial Locations (1)

Unknown

Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Canada, Toronto